Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer

Area of Science:

• Oncology
• Epigenetics
• Pharmacology

Background:

• Advanced prostate cancer often develops resistance to androgen-deprivation therapy (ADT).
• Epigenetic modifications are crucial in cancer development and present potential therapeutic targets.
• ADT resistance significantly impacts patient survival rates in advanced prostate cancer.

Purpose of the Study:

• To evaluate the combined antitumoral effects of hydralazine and enzalutamide in prostate cancer cell lines.
• To investigate the impact of epigenetic modification combined with androgen receptor antagonism on cancer progression.
• To explore novel therapeutic strategies for overcoming ADT resistance in prostate cancer.

Main Methods:

• Prostate cancer cell lines were treated with hydralazine (DNA methylation inhibitor) and enzalutamide (androgen receptor antagonist) individually and in combination.
• Assessed were key biological parameters including cell viability, proliferation, DNA damage, and apoptosis.
• Evaluated were the effects on clonogenic and invasive potential of cancer cells.

Main Results:

• Both hydralazine and enzalutamide demonstrated individual growth-inhibitory effects on prostate cancer cells.
• The combination treatment exhibited synergistic antitumoral activity, surpassing the effects of individual drugs.
• Combined therapy significantly reduced malignant features, including proliferation and invasiveness.

Conclusions:

• The combination of hydralazine and enzalutamide demonstrates potent synergistic antitumoral effects in prostate cancer.
• This combination therapy effectively diminishes key malignant characteristics of prostate cancer cells.
• This drug combination represents a promising alternative therapeutic option for managing advanced prostate cancer, potentially overcoming resistance mechanisms.